References
1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM,
Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi
MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M,
George JN. Standardization of terminology, definitions and outcome
criteria in immune thrombocytopenic purpura of adults and children:
report from an international working group. Blood , 2009 113:
2386–2393.
2. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The
incidence of immune thrombocytopenic purpura in children and adults: A
critical review of published reports. Am J Hematol , 2010 85: 174–180.
3. Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W,
Imbach P, Intercontinental Childhood ITP Study Group, Intercontinental
Childhood ITP Study Group. A prospective comparative study of 2540
infants and children with newly diagnosed idiopathic thrombocytopenic
purpura (ITP) from the Intercontinental Childhood ITP Study Group. J
Pediatr , 2003 143: 605–608.
4. Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. A
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine
the Effect of Romiplostim on Health-Related Quality of Life in Children
with Primary Immune Thrombocytopenia and Associated Burden in Their
Parents. Pediatr Blood Cancer , 2016 63: 1232–1237.
5. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T,
Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C,
McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M,
Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Updated international consensus
report on the investigation and management of primary immune
thrombocytopenia. Blood Adv , 2019 3: 3780–3817.
6. Grainger JD, Thind S. A practical guide to the use of eltrombopag in
children with chronic immune thrombocytopenia. Pediatr Hematol Oncol ,
2017 34: 73–89.
7. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N,
Cuker A, Despotovic JM, George JN, Grace RF, Kühne T, Kuter DJ, Lim W,
McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of
Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv , 2019
3: 3829–3866.
8. Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K.
Improved regulatory T-cell activity in patients with chronic immune
thrombocytopenia treated with thrombopoietic agents. Blood , 2010 116:
4639–4645.
9. Buchanan GR, Adix L. Grading of hemorrhage in children with
idiopathic thrombocytopenic purpura. J Pediatr , 2002 141: 683–688.
10. Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta
Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO,
Wood WA, Savani BN, Kamble RT, Parsons S, Ahmed I, Sullivan K, Beattie
S, Dandoy C, Munker R, Marino S, Bitan M, Abdel-Azim H, Aljurf M, Olsson
RF, Joshi S, Buchbinder D, Eckrich MJ, Hashmi S, Lazarus H, Marks DI,
Steinberg A, Saad A, Gergis U, Krishnamurti L, Abraham A, Rangarajan HG,
Walters M, Lipscomb J, Saber W, Satwani P. Clinical risks and healthcare
utilization of hematopoietic cell transplantation for sickle cell
disease in the USA using merged databases. Haematologica , 2017 102:
1823–1832.
11. Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C.
Corticosteroids versus intravenous immune globulin for the treatment of
acute immune thrombocytopenic purpura in children: a systematic review
and meta-analysis of randomized controlled trials. J Pediatr , 2005 147:
521–527.
12. Second-line treatments in children with immune thrombocytopenia:
Effect on platelet count and patient-centered outcomes - PubMed
[Internet][cited 2021 Jan 13] Available from:
https://pubmed.ncbi.nlm.nih.gov/30945320/
13. Marano M, Serafinelli J, Cairoli S, Martinelli D, Pisani M, Palumbo
G, Cefalo MG, Cecchetti C, Di Nardo M, Falvella FS, Goffredo BM.
Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A
Pharmacokinetic and Pharmacogenetic Analysis. Ther Drug Monit , 2018 40:
386–388.